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Molecular dynamics simulationsG-protein coupled receptors (GPCRs) comprise a large family of membrane proteins with rich functional diversity.
Signaling through the apelin receptor (AR or APJ) inﬂuences the cardiovascular system, central nervous system
and glucose regulation. Pathophysiological involvement of apelin has been shown in atherosclerosis, cancer,
human immunodeﬁciency virus-1 (HIV-1) infection and obesity. Here, we present the high-resolution nuclear
magnetic resonance (NMR) spectroscopy-based structure of the N-terminus and ﬁrst transmembrane (TM)
segment of AR (residues 1–55, AR55) in dodecylphosphocholine micelles. AR55 consists of two disrupted helices,
spanning residues D14-K25 and A29-R551.59. Molecular dynamics (MD) simulations of AR built from a hybrid of
experimental NMR and homology model-based restraints allowed validation of the AR55 structure in the context
of the full-length receptor in a hydrated bilayer. AR55 structural features were functionally probed using mutagen-
esis in full-length AR throughmonitoring of apelin-induced extracellular signal-regulated kinase (ERK) phosphory-
lation in transiently transfected human embryonic kidney (HEK) 293A cells. Residues E20 and D23 form an
extracellular anionic face and interact with lipid headgroups during MD simulations in the absence of ligand,
producing an ideal binding site for a cationic apelin ligand proximal to the membrane–water interface, lending
credence to membrane-catalyzed apelin-AR binding. In the TM region of AR55, N461.50 is central to a disruption
in helical character. G421.46, G451.49 and N461.50, which are all involved in the TM helical disruption, are essential
for proper trafﬁcking of AR. In summary, we introduce a new correlative NMR spectroscopy and computational
biochemistrymethodology anddemonstrate its utility in providing someof theﬁrst high-resolution structural infor-
mation for a peptide-activated GPCR TM domain.
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G-protein coupled receptors (GPCRs) are a large and diverse family
of membrane embedded proteins that are responsible for converting
the extracellular signal of a ligand into an intracellular signal. The im-
portance of GPCRs is mirrored by their abundance, with >750 different
receptors identiﬁed in humans [1]. Beyond their natural physiological
importance, GPCRs are targeted by ~25% of current drugs [2] and have
great potential for pharmaceutical development.
Due to the physiological and pharmacological importance of GPCRs,
there has been considerable drive to characterize them structurally. In
recent years, structures of 11 GPCRs have been determined at high
resolution providing unprecedented insight into GPCR function [3–13].
However, it is important to note that in many cases the extracellular
loops of these structures are poorly resolved or have been mutated in
order to facilitate crystallization. Through these studies, it is clear that a
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GPCRs is responsible for signal transduction by allowing conformational
change upon ligand binding. In particular, transmembrane (TM) segment
VI is shown to undergo considerable movement during activation [14].
However, despite the similarities between structures there are also differ-
ences between them. For example, CXCR4 and rhodopsin contain a kink
in the ﬁrst TM helix while the other solved GPCRs do not.
The apelin receptor (AR or APJ) is a class A, rhodopsin-like GPCR
identiﬁed in 1993 due to high sequence similarity to the angiotensin
receptor AT1 [15]. Angiotensin-II did not activate AR and it remained an
orphan GPCR until 1999 when the endogenous peptide ligand was dis-
covered and named apelin [16]. Various apelin isoforms from 13 to 36
residues in length are produced as C-terminal cleavage products in an
as of yet unspeciﬁed manner from the preproapelin gene product [17].
Since the discovery of AR, it has been shown to be widely
expressed in humans, with high levels in the central nervous system,
cardiovascular system, adipocytes and many other tissues [2]. AR
signaling has key roles in the cardiovascular system, with effects on
vascular smooth muscle cells and a strong inotropic effect on cardiac
muscle [17]. Plasma levels of apelin are correlated to heart failure
progression [17] and body mass index [18]. Furthermore, AR is a
known CD4 co-receptor for HIV type 1 [19].
Modulation of apelin signaling has therefore been identiﬁed as a
therapeutic target, with a handful of non-natural ligands now reported.
Recently, both agonist and antagonist peptide mimics [20–22] have
been discovered based on our previous structural studies of apelin
[23,24]. Blind screens have also been successful, with a non-peptidic
agonist being discovered through a FRET based assay [25]. However,
there are no published experimental structural data for AR itself, ham-
pering the drug discovery process. Furthermore, there are no published
structures of peptide binding GPCRs, making it unclear as to howmany
conclusions can be drawn from homologous structures.
At the molecular level, there have been two mutagenesis studies
probing binding to and activation of AR by apelin. However, the cov-
erage of the receptor is too sparse to make many conclusions about
the ligand binding site or mechanism of activation. Zhou et al. [26]
showed insensitivity to deletion of the ﬁrst 10 residues of AR vs. a
complete disruption of apelin binding competency upon deletion of
the ﬁrst 20 residues. Speciﬁcally, the E20A and D23A mutations
prevented apelin binding despite normal receptor localization. Iturrioz
et al. [27] demonstrated that mutation of W1524.50 in rat AR TM IV
affected folding while F2556.44 and W2596.48 mutants still allowed
apelin binding but prevented AR internalization (Ballesteros nomencla-
ture shown as superscript for TM residues [28]).
Full-length membrane proteins are challenging to characterize
structurally [29]. The “divide and conquer” approach provides a tracta-
ble route to collect structural information about a membrane protein of
interest. In this approach, dissected segments ofmembrane proteins are
studied in a membrane mimetic environment. The underlying assump-
tion, following from the multi-step cycle of membrane protein folding
[30–33], is one of structural integritywith the same segment in the con-
text of a full-length protein [34]. Although protein tertiary structure
must be determined through other methods, the divide and conquer
approach applied judiciously can provide reliable data about secondary
structure and has been applied to several other GPCRs [35–43].
In this paper, we provide the NMR spectroscopy-derived high-
resolution structure of the N-terminal tail and ﬁrst TM segment of
AR solubilized in dodecylphosphocholine (DPC) micelles. Residues
involved in a TM domain helical disruptionwere subjected tomutagen-
esis, highlighting their involvement in functional AR folding. The NMR-
based structure of AR55 was placed in the context of full-length AR
using structural calculations and molecular dynamics simulations com-
bining the experimental restraints and a CXCR4-based homologymodel
of full-length AR. Considered in the perspective of mutagenesis data
presented here and previously, key structural features for both AR
folding and apelin binding are brought to light.2. Materials and methods
2.1. Materials
pEXP5-CT vector, fetal bovine serum (FBS) and reagents for
polymerase chain reaction (PCR) ampliﬁcation of DNA were obtained
from Invitrogen (Burlington, ON). A synthetic gene with bacterial
codon optimized AR55 coding sequence as well as DNA primers for
PCR ampliﬁcation and mutagenesis were purchased from BioBasic
Inc. (Markham, ON). Phusion and QuikChange mutagenesis kits
were obtained from New England Biolabs (Pickering, ON) and Strata-
gene (Wilmington, DE), respectively. The cDNA clone for 3×-human
inﬂuenza hemagglutinin (HA)-tagged human AR was obtained from
the Missouri S&T cDNA Resource Center (www.cdna.org). cOmplete
Protease Inhibitor Cocktail tablets were obtained from Roche (Laval,
QC). HPLC grade acetonitrile, ampicillin, bovine serum albumin (BSA),
dithiothreitol (DTT), isopropyl β-D-1-thiogalactopyranoside (IPTG),
triﬂuoroacetic acid (TFA) and reagents for making Luria Broth (LB) me-
diumwere purchased from Fisher Scientiﬁc (Ottawa, ON). Uniformly
13C enriched D-glucose and 15N enriched NH4Cl were purchased from
Cambridge Isotope Laboratories (Andover, MA). Deuterated DPC
(DPC-d38), DTT-d6, deuterium oxide (D2O; 99.8 atom % D) and D2O
containing 1% (w/w) sodium 2,2-dimethyl-2-silapentane-5-sulfonate
(DSS) were obtained from C/D/N isotopes (Pointe-Claire, QC). 0.2 μm ﬁl-
ters were obtained from Millipore (Billerica, MA). Primary anti-HA anti-
bodies were obtained from either Covance (Montréal, QC) or Santa Cruz
Biotechnology Inc. (Santa Cruz, CA). Non-cross reactive anti-rabbit
Dylight 549 conjugated and anti-mouse Dylight 649 conjugated antibod-
ies were purchased from Rockland (Gilbertsville, PA). Donkey
anti-mouse, Cy5 conjugated antibodies were obtained from Jackson
ImmunoResearch (West Grove, PA). Paraformaldehyde was obtained
from Electron Microscopy Sciences (Hatﬁeld, PA) and ﬂuorescence
mounting medium was obtained from Dako (Burlington, ON). All
other chemicals were obtained from Sigma-Aldrich (Oakville, ON).
2.2. Cloning and expression of AR55
PCR was used to amplify the purchased AR55 gene and clone it
into pEXP5-CT vector. Sequencing (Biobasic Inc.) was used to check
for correct vector insertion of the PCR product to code for the following
amino acids: MEEGGDFDNY YGADNQSECE YTDWKSSGAL IPAIYMLVFL
LGTTGNGLVL WTVFRKKGHH HHHH, corresponding to the ﬁrst 55
residues of AR as well as a C-terminal KKG extension and His6-tag.
High yield expression of uniformly 13C/15N-labeled AR55 (~5 mg/L)
was achieved with BL-21(DE3) Escherichia coli grown in LB medium to
an optical density at 600 nm (OD600) of 0.6 and transferred to a 1/2-
equivalent volume of minimal medium (100 mM NaH2PO4, 40 mM
K2HPO4, 4 mM MgSO4, 1.8 μM FeSO4, 2 g/L 13C6 D-glucose, 1 g/L of
15NH4Cl and 100 mg/L ampicillin, titrated with NaOH to pH 7.3), as in
Markley et al. [44]. Expression was induced by adding IPTG to 0.5 mM
followed by shaking (37 °C, 4 h) and centrifugation of the cells
(3000 ×g, 15 min).
2.3. Puriﬁcation of AR55
Cell pellets were resuspended (50 mM Tris–HCl buffer, pH 8.0, 25%
w/v sucrose, 1 mM EDTA, 0.1% w/v NaN3, 5 mM MgCl, 0.03 mg/mL
DNase I and 1% Triton-X 100), sonicated and centrifuged (15,000 ×g,
30 min). The pellet was washed 4× (50 mM Tris–HCl buffer, pH 8.0,
0.5% Triton-X100, 100 mM NaCl, 1 mM EDTA). The resulting inclusion
body-containing [45] pellet was resuspended in acetonitrile:H2O (1:1
v:v) containing 0.1% TFA, ﬁltered using a 0.2 μm ﬁlter and reduced
with DTT at ~100 mM prior to reverse phase HPLC (Cosmosil C18
column, linear gradient from 45% to 65% acetonitrile in H2O, 0.1% TFA
over 15 min using a Beckman System Gold (Mississauga, ON)). Peaks
were collected and immediately lyophilized, with AR55 peak identity
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Micromass M@LDI instrument (Waters; Mississauga, ON).2.4. NMR spectroscopy of AR55
AR55 (1 mM) was prepared in 90% H2O/10% D2O containing
150 mM DPC-d38, 20 mM Na+CD3COO−, 1 mM DSS, 1 mM NaN3 and
10 mM DTT-d6 at pH 4.00±0.05, without accounting for deuterium
isotope effects. This low pHwas employed due to precipitate formation
in AR55/DPC micelle samples above pH 4.5. 1H–15N heteronuclear
single quantum coherence (HSQC), HNCO, HNcaCO, HNCA, HNcoCA,
HNCACB, HNcoCACB (500 MHz) as well as 15N-edited nuclear
Overhauser enhancement (NOE) spectroscopy (NOESY; 800 MHz,
125 ms mixing time following from a buildup curve for AR55 in non-
deuterated lyso-palmitoyl phosphatidylglycerol micelles [46]) experi-
ments were acquired using Varian (Palo Alto, CA) INOVA instruments
at the QANUC Facility (Montreal, QC). HcCH total correlation spectros-
copy (TOCSY) and 13C-edited NOESY (125 ms mixing time) experi-
ments were collected using a 700 MHz Bruker (Milton, ON) Avance III
spectrometer at the NRC BMRF/NMR3 Facility (Halifax, NS).2.5. NMR structure calculation of AR55
NMR data were processed using NMRPipe [47] and analyzed man-
ually using CCPNMR Analysis version 2.1.5 [48] following the main
chain directed approach [49]. 3D-NOESY peak volumes were binned
into distance restraint classes of 1.8–2.8 Å, 1.8–4 Å, 1.8–5 Å and 1.8–
6 Å using CCPNMR Analysis. Following previous protocols [50], 100
member NOE-based ensembles were produced in XPLOR-NIH version
2.19 [51,52] and iteratively reﬁned using a Tcl/Tk script to identify
violating restraints requiring reassignment or lengthening due to poor
peak integration and overlap. 11 rounds of iterative structure calcula-
tion led to a converged AR55 structural ensemble, as indicated by
reported XPLOR-NIH total energies and minimal restraint violation.
The 40 structures with lowest energy were retained in the ﬁnal ensem-
ble and validated with PROCHECK-NMR [53]. ϕ and ψ dihedral angle
order parameters were analyzed to determine regions of converged
structure, as detailed in [54]. Helical kink angles in the NMR ensemble
were measured using the MC-HELAN algorithm [55].2.6. General molecular dynamics (MD) simulation parameters
MD simulations were used both for building of the AR homology
model (Section 2.7) and evaluating the validity of the “divide and
conquer” derived NMR structure of AR55 in the context of the full-
length AR in a lipid bilayer (Section 2.8). In all cases, MD simulations
were carried out using the GROMACS 4.5.4 [56] software package,
using the GROMOS53a6 forceﬁeld [57]. Topology ﬁles were produced
by standard GROMACS methodology. In all cases, structures were ﬁrst
subjected to a 200-step steepest descent energy minimization.
Following this, canonical ensembles were subjected to 100 ps of sim-
ulation at 323 K, with a coupling constant of 0.1 ps. After stabilization
of temperature, isothermal–isobaric ensembles were subjected to 1
bar pressure with a coupling constant of 5 ps for 1 ns. After equilibra-
tion, semiisotropic pressure coupling was introduced at 1 bar with a
coupling constant of 1.0 ps for extended MD simulations suitable for
analysis. In all cases, simulations were performed using the Nose–
Hoover thermostat [58], and Parrinello–Rahman pressure coupling
[59]. The Particle Mesh Ewald (PME) method [60] was employed for
long-range electrostatics, with 1.2 nm cutoff for van der Waals and
Coulomb interactions, updating every 10 fs. The LINCS algorithm [61]
was used for covalent bond constraints, with periodic boundary con-
ditions in all dimensions. In all cases, the system was stable for the
length of the MD simulations indicated.2.7. NMR restraint-informed homology modelling of AR
A homology model for AR was built based on the 2.5 Å X-ray
CXCR4 structure (3ODU, [9]), with pairwise alignment using the
conserved class A GPCR TM segment residues [62]. Insertions of Gly
spacers or deletions were used to rectify length discrepancies in loops
and termini. Each insertion or deletion was performed by producing a
high-energy modiﬁed protein structure and subjecting it to a short
(~2 ns) in vacuo MD simulation to allow polypeptide backbone relaxa-
tion. Conserved TM domain residue sidechains were ﬁxed using the
CXCR4 template for substitution of all required sidechains by SCWRL 4
[63]. The resulting model was subjected to a 10 ns MD simulation in
vacuo.
From this initial model, distance restraints in the 5–12 Å range
(±1.4 Å from initial distance) were produced using 1H–1H distances
within the TM domain. All restraints were retained for highly con-
served residues vs. 30% elsewhere to reduce computational demand.
Backbone dihedral angle restraints (±40° from starting model)
were calculated over the TM II–VII regions. These, along with the
experimental AR55 NOE restraints and the disulﬁde bonds predicted
for the extracellular domain [64], were used in and reﬁned by XPLOR-
NIH simulated annealing calculations. Potential scaling was carried
out as in Section 2.5, with separate treatment of experimental NOEs
and pseudo-NOEs. Unlike reﬁnement of NMR-based structures, reﬁne-
ment of the model included only modiﬁcation of model NOE-like and
dihedral restraints, with ﬁxed stringency. Those NOE-like restraints vi-
olating by >0.3 Å in >70% of structures were removed, while those vi-
olating by >0.3 Å in >50% of structures were lengthened by a 0.2 Å. In
the case of dihedral restraints, those violating by >10° in 80% of struc-
tures were widened by 5° iterations. Following 8 rounds of reﬁnement
by thismethod,model NOE-like restraints, and experimental NOEs con-
tributed minimal energies to the structures. A ﬁnal ensemble of 72
members was produced, from which the 18 with lowest energy were
retained.
2.8. MD simulations and trajectory analysis of full-length AR
An arbitrarily selectedmember from the ensemble of NMR restraint-
informed homology models (the selected member had no violations of
experimental NOEs by >0.5 Å and a rootmean squared violation size of
0.022 Å for all experimental NOEs) was subjected to replicate MD
simulations in explicit, hydrated dipalmitoylphosphatidylcholine
(DPPC) bilayers. Protein and lipid were separately temperature-
coupled to an external bath at 323 K with a 0.5 ps time constant
(parameters based upon [65]). Membrane insertion of the AR model
was performed at the center of a DPPC bilayer (482 molecules), with
the AR long axis perpendicular to the membrane–solvent interface.
This process was aided by the g_membed [66] computational tool. The
membrane was then solvated with 41,148 water molecules using
the simple point charge (SPC) model, and was neutralized via the
replacement of arbitrary solvent with Cl− counter-ions. Two replicate
simulations were performed for 100 ns each. For analyses of non-
time-dependent behavior over trajectories, the ﬁrst 10 ns was
disregarded in each case. Backbone dihedral angle order parameters
(following Section 2.5), AR55 NOE violations (following Section 2.5),
H-bonding patterns for N46 (based upon standard geometries,
e.g. [67]) and the projected angle of the E20 and D23 sidechains over
the course of the MD trajectories were determined using in-house tcl
(dihedral angle and E20/D23 analysis) and Python code (NOE violations
and H-bonding) to analyze Protein Data Bank (PDB) format ﬁles pro-
duced from simulation frames separated by 0.1 ns intervals (every 50
frames). The freely-available Reduce software package [68] was used
to reintroduce protons to the PDB ﬁles for those analyses requiring ex-
plicit protons, as GROMOS53a6 is a united-atom forceﬁeld without ex-
plicit aliphatic (non-polar) hydrogens. For RMSD, area per lipid,
bilayer thickness and anionic face contact calculations described
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analyzed using in-house Python code.
2.8.1. Tracking protein RMSD
Backbone atoms in the AR models were included in RMSD calcula-
tions and the reference structure was taken from the ﬁrst frame of the
ﬁrst replicate simulation. For each replicate, the instantaneous protein
coordinates in every hundredth frame (every 0.2 ns) were translated
and rotated to produce anRMSD-minimized superpositionwith the ref-
erence structure [70,71]. An unweighted RMSD value was derived from
the optimized superposition.
2.8.2. Area per lipid calculations
In every hundredth frame (every 0.2 ns) of the two replicate
trajectories, the AR coordinates were used to deﬁne a central rectangu-
lar ‘exclusion zone’ in the xy-plane inside which no DPPC atoms were
included in area per lipidmeasurements. As AR is an irregular geometric
object, this vastly simpliﬁes the calculation of the area occupied by
DPPC at the cost of excluding approximately 15% of all DPPC atoms in
each frame. The net area occupied by the remaining DPPC atoms was
calculated as the difference between the areas of the complete simula-
tion box and the exclusion zone (xy-plane). Some DPPC molecules
straddled the exclusion boundary, but for higher accuracy those atoms
that were outside the exclusion zone were nonetheless included to
produce a fractional number of DPPC molecules to be considered in
each analyzed frame. The average area per DPPC molecule was then
calculated by dividing double the net exclusion area of a single leaﬂet
by the fractional number of excluded DPPCmolecules from both leaﬂets
combined. The average area and standard deviation across the two
replicates, excluding the ﬁrst 10 ns of each replicate to allow for equil-
ibration (900 frames considered), were also calculated.
2.8.3. Bilayer thickness calculation
DPPC phosphate atomswere assigned to a given leaﬂet only if they
were within a given distance cutoff of another phosphate atom in that
leaﬂet. In every 100 frames (every 0.2 ns), distance cutoffs for this
networking procedure were optimized by varying between 3 and
17 Å in 2 Å steps, but in some cases the MDAnalysis-based algorithm
could not identify two distinct leaﬂets. Phosphate particles within 12 Å
of the phosphate center of geometry of the bilayer were excluded from
analysis to prevent propagation of the selection network from one leaf-
let to the other. Only in rare caseswas the algorithmnot able to uniquely
identify two leaﬂets, and in all frames the two largest networks of phos-
phate particles retained a consistent population suitable for estimating
bilayer thickness. The last 90 ns of the two 100 ns replicate simulations
was parsed for the phosphate center of geometry (Z coordinate) separa-
tion between leaﬂets either within an 18 Å shell of the protein or
outside of it. The average and standard deviation of interphosphate
bilayer thickness were both calculated.
2.8.4. Anionic face sidechain and contact analysis
Angles between the E20 and D23 sidechainswere determined every
50 frames (every 0.1 ns) (i) through calculation of the pseudo-torsion
angles between the centroids of the sidechain oxygens of each residue
and the closest backbone heavy atom within one residue N- or
C-terminal to each anionic residue and (ii) through the CB-CA-CA-CB
torsion angle. Every 500 frames (every 1 ns) from the last 90 ns of the
replicate trajectories was parsed for the full set of atoms within a 5 Å
shell of the sidechain oxygens of either E20 or D23. Every residue in
the topology (amino acid, DPPC molecule, or water molecule) was
counted as a contact in a given frame if any of its atoms fell within
one of these shells, and there was no duplicate counting of a given res-
idue if many of its atoms fell within a given shell. The aggregate residue
contact counts were normalized to the total number of frames parsed
and the top ten most likely proximal residues were sorted for both
E20 and D23 sidechain oxygens.2.9. Mutagenesis, ERK phosphorylation assays and immunoﬂuorescence
microscopy
Single-point Ala and Ile mutants of 3HA-tagged AR were generated
at G421.46, T431.47, T441.48, G451.49, N461.50 and G471.51 alongside
N46DandN46Qusing Phusion orQuikChangemutagenesis kits.Mutant
constructs were sequenced for exactitude. HEK 293A cells were seeded
into 6 well plates and grown in Dulbecco's modiﬁed eagle medium
(DMEM) containing 10% FBS. At ~50% conﬂuence, cellswere transfected
by adding 100 μL of a solution containing 2 μg of DNA, 20 μg of
polyethylenimine (PEI) and 100 μM DMEM. The media was aspirated
and replaced with DMEM 8 h later and stimulated 24 h
post-transfection with 1 μM apelin-17 for 5 min. The cells were
harvestedwith 1 mL of PBS, resuspended in 80 μL of radioimmune pre-
cipitation assay buffer (50 mM Tris, pH 7.5, 10 mM MgCl2, 150 mM
NaCl, 0.5% sodium deoxycholate, 1% Nonidet P-40, 0.1% SDS, Complete
Protease inhibitors, DNase I, 2 mM sodium orthovanadate and 1 mM
sodium ﬂuoride) and 20 μL of 5× SDS sample loading buffer, and cells
were heated to 65 °C for 10 min. The lysate was resolved by
SDS-PAGE on 12% polyacrylamide gels at 200 V for 45 min, with trans-
fer onto nitrocellulose membrane at 115 V for 75 min. Membranes
were incubated in blocking buffer (Tris buffered saline with 2% w/v
BSA) for 1 h before overnight incubation at 4 °C in blocking buffer
with primary antibodies for extracellular signal-regulated kinase
(ERK; polyclonal rabbit anti-HA, 1:1000) and phospho-ERK (monoclo-
nal mouse anti-HA, 1:500). Secondary antibodies (1:2000 donkey
anti-rabbit Dylight 649 conjugated; 1:1000 donkey anti-mouse Dylight
549 conjugated) in blocking buffer were applied for 1 h. After ﬁnal
washing and drying the membrane was imaged on a VersaDoc 4000
(Biorad; Mississauga, ON).
For immunoﬂuorescence microscopy, human embryonic kidney
(HEK) 293A cells were grown on coverslips in DMEM containing 10%
FBS until ~50% conﬂuence. Transfection was performed as above, with
the exception that only 12 μg of PEI was used and media was refreshed
with DMEMwith 10% FBS. Cells were washed in warm PBS and ﬁxed in
2% paraformaldehyde in PBS for 10 min 24 h post transfection. Cover-
slips were blocked with PBS containing 5% normal donkey serum for
20 min then incubated with primary antibody for 1 h (1:1000 mouse
anti-HA). After washing 3× in PBS for 5 min, coverslips were incubated
with secondary antibody (1:500 donkey anti-mouse, Cy5 conjugated)
for 30 min and mounted using ﬂuorescence mounting medium. Fluo-
rescence imageswere acquired on a Zeiss AxioObserver Z1 invertedmi-
croscope (Intelligent Imaging Innovations (3i); Boulder, CO) using a
solid state spectra light source (Lumencor; Beaverton, OR). Cells were
observed using a 40× objective (1.3 N.A) and images were recorded
using an HQ2 charge-coupled device camera (Photometrics; Tucson,
AZ) and Slidebook 5.0 software (3i; Boulder, CO). For each AR mutant,
at least three representative ﬁelds of view containing 5–10 cells each
were collected. Photoshop CS5 (Adobe) was used to adjust brightness
and crop images.
2.10. Database accession details
The structural coordinates for the ﬁnal ensemble of AR55 have
been deposited in the PDB ([72]; accession # 2LOU). The chemical
shift, spectral peak list and restraint data have been deposited to
the Biological Magnetic Resonance Bank (BMRB [73], accession #
18225).
3. Results
3.1. Structure of AR55 in DPC micelles
Despite chemical shift overlap typical of a helical TM domain,
spectral quality of AR55 in DPC micelles was sufﬁcient to assign all
64 residues (Fig. 1) through the main chain directed backbone walk
Fig. 1. Two-dimensional 1H–15N HSQC spectrum of AR55 solubilized in DPC micelles at
37 °C at 700 MHz 1H frequency. (B) Zoom to the region boxed inA,with peak assignments
annotated. Aliased peaks are indicated with *'s.
Fig. 2. Summary of NOE assignments for AR55 in DPC micelles. (A) Distance restraints on
distance restraints, chemical shift index [75] and DANGLE secondary structure prediction [7
Table 1
Distance restraints, violations and Ramachandran plot statistics of the 40-member





Medium range (|i–j|≤4) 161











NOE violations>0.5 Å 0
NOE violations of 0.3–0.5 Å 1
NOE violations>0.2–0.3 Å 0
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86% of 13C and 80% of 15N nuclei (BMRB Entry #18225). Some slow-
exchange conformational sampling is also apparent in the form of
minor, unassigned peaks in the 1H–15N HSQC spectrum (Fig. 1) and
other triple-resonance experiments (not shown), most likely arising
from conformational exchange in the N-terminal tail of AR55.
In total, 841 unique distance restraints were determined (Fig. 2;
Table 1). The distribution of distance restraints is not uniform through-
out the protein, with the N-terminal tail of AR55 (residues ~1–28)
having fewer medium range restraints than the putative membrane-
spanning region (residues ~29–51, Fig. 2A). Of the assigned distance re-
straints, canonical i,i+3 and i,i+4 helical contacts [74] are primarily
observed from A29-L401.44 and from T441.48-R551.59, with some in thea per-residue basis (short is |i–j|=1; medium is |i–j|≤4). (B) Graphical overview of
6] generated using CCPNMR Analysis [48].
Fig. 3. Structure of AR55 in DPC micelle solution and in context of MD simulations of full-length AR in hydrated DPPC bilayer. (A–D) are superpositions of the 40-member AR55
NMR-based structural ensemble. In (A–B), the kinked helical TM domain (A29-K571.61) of AR55 is shown superposed over (A) A29-N461.50 (blue) or (B) G471.51-K571.61
(green). In (C–D), all four structurally converged regions of the NMR ensemble are superposed, with D14-C19 in orange, E20-K25 in dark red, A29-N461.50 in blue and
G471.51-K571.61 in green; the E20 and D23 sidechains are shown for all 40 ensemble members with positions based on the backbone superposition of E20-K25. In (C), the
superposition is onto the lowest-energy conformer of the NMR ensemble (backbone shown in black); in (D), onto a frame from the replicate MD simulation of full-length AR
(backbone of residues 1–55 illustrated in black) of the 40 randomly selected frames in (F) with the lowest overall RMSD over the converged regions. (E) Detailed conﬁguration
of an arbitrary, representative simulation frame, including sidechain positions of T431.47, T441.48 and N461.50 (blue sticks), S3027.46 and N3057.49 (orange sticks) and a water
molecule associated with TM I kink (red/grey). H-bonds in (E) are illustrated by dashed black lines. (F) Superposition over all 7 TM domains of 40 random frames from the AR
simulation upon AR simulation frame used in D (colouring over AR55 region as in D). Spheres in D and F are phosphorus atom positions in proximal DPPC headgroups for the sim-
ulation frame used in D. All panels were produced in PyMol (Schrödinger).
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that AR55 is largely helical from D23-K571.61. Finally, the DANGLE
algorithm [76] predicts the membrane spanning region of AR55 to be
composed of two helices with a disruption in helical character from
G42-N46 and the presence of a third helix in the N-terminal tail of
AR from N15-K25 (Fig. 2B). Taken together, these data imply a helix
from ~A29-K571.61 alongside some additional helical character in the
N-terminal tail.Using the NOE derived distance restraints, a structural ensemble
(Fig. 3A–C; 40 lowest energymembers of 100 calculated)was generated
in excellent agreementwith the experimental data (Table 1). Analysis of
dihedral angle variability in the structural ensemble [54] indicates
that the D14-C19, E20-K25, A29-N461.50 and G471.51-K571.61 regions
of AR55 are well converged (Fig. 4A–B; Supplementary data Fig. S1).
Superposition yields backbone atom root mean square deviation
(RMSD) values of 0.70, 0.66, 1.33 and 0.99 Å for these 4 regions over
Fig. 4. Polypeptide backbone dihedral angle convergence in the AR55 NMR derived ensemble and replicate MD simulations. Dihedral angle order parameters [54] are shown for ϕ
(A and C) and ψ (B and D) over the 40-member AR55 NMR ensemble (A and B; dashed lines) and for the ~60 ns replicate MD simulation trajectories (A–D, solid lines). All helical
regions of AR55 are shaded in A and B, while the TM helices are shaded in C and D.
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of the N-terminal tail and the His6-tag, is largely variable between en-
semble members.
The N-terminal tail of AR55 has helical character from D14-K25,
with a pivot point at C19-E20 allowing conformational sampling [54]
of the helical segments to either side. The E20 and D23 sidechains fall
on the same face of the E20-K25 helical segment, producing an anionic
surface (Fig. 3C). The region of AR55 corresponding to TM I in AR has ahelix-kink-helix structure, with the kink occurring in the relatively
polar region (GTTGNG) around N461.50. A break in helical character at
the kink is evident both from a lack of the characteristic helical NOE
contacts in its vicinity and from the deviation away from chemical
shift-based helix prediction at the kink according to both CSI and
DANGLE. It should be noted that the relative positions and orientations
of each section of the TM helix are not well deﬁned (Fig. 3A–B). The
observed variability in relative helix position and orientation is due to
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awide variability in the calculated kink angle [55], with amean value of
69±20°. While the relative orientations of the helical segments of the
TM domain could likely be better deﬁned using an approach such as
measurement of residual dipolar couplings [49], thiswould be relatively
challenging to perform in a cost-effective manner due to the extensive
spectral overlap of 2D NMR experiments on AR55 (e.g., Fig. 1A) and rel-
atively short transverse relaxation time constants for residues in the TM
domain (average 15N T2 of ~45 ms over residues 30–54) with corre-
spondingly broad linewidths.We have therefore opted instead to char-
acterize this in the context of full-length AR usingMD simulations on an
NMR restraint informed homology model (Section 3.3).3.2. Function of 3xHA AR mutants
Following previous demonstration of AR stimulation leading to ERK
phosphorylation in AR transfected HEK 293A cells [77], this process was
monitored for transiently transfected 3xHA AR mutants upon stimula-
tion with 1 μM apelin-17 for 5 min. Mutation of G421.46, G451.49 and
N461.50 impaired AR activation compared to wild-type AR, with muta-
tion to Ile having a more pronounced effect than mutation to Ala
(Fig. 5). N461.50 was particularly sensitive to mutation, with N46A,Fig. 5. Functional analysis of 3xHA AR mutants. The fold ERK phosphorylation compared to w
experiment in (A) and plotted for all replicates in (B) for all mutants alongside the empty ve
least 3 times (*=pb0.05; **=pb0.01).N46D and N46I mutants all having severely impaired activation. The
N46Q mutant, conversely, had approximately wild-type activity.
Through immunoﬂuorescence microscopy, the general localization
of 3xHA AR and each of the AR mutants was established. For the
wild-type receptor andmutants with approximately wild-type activity,
propermembrane trafﬁcking and localization of 3xHA ARwas apparent
(Fig. 6; Supplementary data Fig. S2). Conversely, mutants with
decreased activation (G42I, G45I, N46A, N46D and N46I) showed
abnormal receptor localization on the membrane surface due to either
improper trafﬁcking or folding.
3.3. Simulation-based context for AR55 structure
A homology model of AR based on a 2.5 Å crystal structure of the
related GPCR CXCR4 [9] was built. NMR-styled distance and dihedral
angle restraints were produced using the model and supplanted by
the NMR-derived restraints (Table 1; Fig. 2) in the AR55 region.
Following simulated annealing structure calculations, an arbitrary
member of the ensemble of NMR restraint-informed homology models
was embedded into a hydrated DPPC bilayer and simulated twice using
uniﬁed-atom MD methods for 100 ns. Simulations were performed in
the complete absence of any distance or dihedral restraints and were
carried out usingwell-parameterizedDPPC bilayerswith physiologicallyild-type 3xHA receptor (AR) after stimulation by apelin-17 is shown for a representative
ctor control (PcDNA 3.1+). Standard error is shown, with each experiment replicated at
Fig. 6. Distribution of 3xHA AR in transiently transfected HEK 293A cells. Immunoﬂuorescence microscopy showing a differential interference contrast (DIC) ﬁeld of view overlaid
by the signal from Cy5 bound to 3xHA AR is shown for WT AR and the functionally inhibited mutants. Scale bars are 10 μm.
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tions was validated both in terms of AR behavior and phospholipid
behavior.
The RMSD of the AR reached a reasonably stable plateau in the
two 100 ns replicate simulations (Fig. 7A), and the ﬁrst 10 ns was
discarded for the purpose of several analyses in order to allow for
equilibration. Only backbone atoms of the AR are considered in this
analysis of structural deviation relative to the ﬁrst frame of the ﬁrst
replicate simulation. Examination of ϕ and ψ dihedral angle order
parameters over the course of the merged 180 ns MD trajectory dem-
onstrates well maintained structure in the TM domains (Fig. 4C–D)
and more variability in the loops and termini. This is evident in the
ensemble of 40 randomly chosen AR frames (20 from the last 90 ns of
each replicate) superposed in Fig. 3F and provided as a PDB ﬁle in the
Supplementary data. In terms of bilayer behavior, the average area per
DPPCmoleculewas tracked as a function of time in each of our replicate
AR MD simulations (Fig. 7B). The trends are stable and similar for the
two replicates, consistent with an equilibrated system (i.e., a properly
packed bilayer). Our overall average area per lipid at 323 K (61.0±0.8
Å2) is consistent with previous MD simulations of pure DPPC bilayers
at 323 K reporting values of: ~62 Å2 [78], 62±1 Å2 [79], ~64 Å2 [80],
64.7±0.2 Å2 [81], 64.5±1.0 Å2 [82], 65±1 Å2 [83], and 66.8±0.7 Å2
at 350 K [84]. It is also noteworthy that the presence of a dynamic
membrane protein in our simulations could be reasonably expected to
modestly inﬂuence the average area per lipid, perhaps causing slightly
tighter packing. Although occasional protein-local thinning of the
DPPC bilayer was observed by visual inspection of the trajectories, a
quantitative analysis of the average interphosphate bilayer thickness
within an 18 Å shell of the AR (37.9±0.7 Å) and outside of this shell
(37.4±0.5 Å), over 2×90 ns of simulation time, does not provide
signiﬁcant evidence of bilayer thinning within one standard deviation.As a whole, the models derived from simulated annealing and the
subsequent MD simulation trajectories are in good agreement with
the experimental structure of AR55 (Fig. 3D) and mutagenesis data.
While the initial models produced using NMR structure calculation
protocols violated no experimental distance restraints, MD simulation
led to AR conformations where ~10% of the unique NOEs would be
violated in >50% of the frames sampled (Supplementary data Table
S1) with varying degrees of mismatch between the NMR data and
the simulation. NOE “violations” in theMD trajectories are not localized
to a particular region of AR55, rather they are spread over the entire
55 residue segment. Of the NOEs violated in >5% of frames (Supple-
mentary data Table S1), >80% involve one ormore sidechain atoms, im-
plying variant positioning of sidechains between the isolated AR55
segment and the full-length, bilayer embedded protein. Notably, the
backbone atom-only NOE contacts that were violated almost exclusive-
ly fell in the N-terminal tail or intracellular loop 1 portions of AR55 (the
same regions which display lower ϕ/ψ dihedral order parameter indic-
ative of increased dynamics), with only 4 TM domain backbone NOEs
producing an appreciable number of violations and all localized around
the kink. The modest mismatch observed between the experimental
AR55 distance constraints andMD trajectories is therefore likely almost
exclusively caused by variation in sidechain positions and in backbone
conformational dynamics outside of the TMdomain. As such, the exper-
imentally converged regions of AR55 agree well with stable structuring
during the MD simulation trajectories, as is readily seen in superposi-
tion of the NMR ensemble over each of these regions upon an arbitrary
simulation frame (Fig. 3D) and, more generally, in examination of the
backbone dihedral angle order parameters for the set of MD trajectories
over the AR55 region (Fig. 4A–B). Speciﬁcally, high dihedral angle order
is seen in the helical transmembrane region but not near N461.50, which
is where the kink is observed in AR55. Throughout the course of theMD
Fig. 7. Tracking protein and lipid behavior in the molecular dynamics simulations.
(A) The RMSD of backbone heavy atoms in the apelin receptor was tracked over the
length of each trajectory with reference to the ﬁrst frame of the ﬁrst replicate simulation.
(B) The area per DPPC molecule was tracked in each replicate simulation after excluding
all atoms and the corresponding area occupied by a rectangular zone bounding the apelin
receptor. For both analyses, every tenth data point was plotted to improve clarity.
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kink falls within the hydrophobic tailgroup region of the bilayer (e.g.
the approximate DPPC headgroup phosphatemoiety positions illustrat-
ed in Fig. 3D and F).
Although more variation in backbone structure is apparent in the
MD trajectories than in the NMR ensemble over the N-terminal tail,
in most of the simulation frames, the region surrounding E20 and
D23 is ordered, with the sidechains of these residues forming anTable 2
Identities of the ten most frequently observed interacting residues for the E20 and D23
sidechain oxygens during the last 90 ns of two 100 ns MD simulation trajectories.
Residue in
topology




% frames within 5 Å of
D23 sidechain oxygens
K25 9.9 L30 34.1
DPPC (658) 14.3 A29 36.3
C19 17.0 G28 44.5
Q16 26.4 DPPC (406) 55.5
W24 46.2 S27 56.0
D23 51.1 DPPC (496) 57.1
Y21 55.5 DPPC (404) 59.9
T22 66.5 T22 64.3
DPPC (406) 95.6 W24 78.6
E20 100.0 D23 100.0anionic surface. Over both MD trajectories, the torsion angle between
the vectors formed between the closest backbone heavy atom and the
centroid of the sidechain Oγ or Oδ atoms for these two residues had a
mean of 9.0±35.3° (range −123.1°–104.0°; Fig. S3) while these
centroids were separated by a mean distance of 8.9±3.2 Å (range
4.3–15.6 Å). The E20 and D23 sidechain oxygens both localized prom-
inently near DPPCmolecules (Table 2; Fig. 3D and F), with most of the
prominent amino acid interactions for E20 and D23 falling proximally
within primary sequence rather than on neighbouring transmem-
brane segments or extracellular loop segments.
4. Discussion
4.1. A kink is present in TM I of AR in a functionally sensitive region
In the AR55 NMR ensemble, a kink is present near residue N461.50.
This kink is observed both in the isolated AR55 NMR structural
ensemble and throughout the replicate MD trajectories on full-length
AR in a hydrated bilayer (Fig. 3). During the MD trajectories, the exact
kink location varies to some degree, generally falling close to T441.48
(Fig. 3F). Notably, both ground state and light activated bovine rhodop-
sin (PDB entries 1F88 and 4A4M) aswell as inactive CXCR4 (3OE6) have
kinks in TM I in proximity to the homologous position of the kink in
AR55. In the case of rhodopsin, this clearly arises from a kink-inducing
Pro residue [55] at position 1.48. It has been shown that TM
helix kinks may arise from vestigial prolines [85]; however, none of
the known AR sequences from related organisms include a proline
residue near T441.48, making this explanation for the kink unlikely.
CXCR4 is kinked at position 1.49 (as determined by the MC-HELAN
algorithm [55]) but is hydrophobic at positions 1.47 and 1.48, with a
sequence of G1.46IVGNG1.51 corresponding to G1.46TTGNG1.51 in AR.
Notably, a number of other GPCR structures (e.g. the squid rhodopsin
(2Z73), several β2-adrenegric (2R4R, 2R4S, 3D4S, 3KJ6, 3NY8, 3NY9,
3NYA, 3SN6), two adenosine A2A (3EML, 3QAK), the dopamine D3
(3PBL) and the sphingosine 1-phosphate (3V2W) receptor structures)
have an unkinked TM I.
In order to evaluate the importance of this kink, functional effects
of mutations in its vicinity were tested. As is clear from both ERK
phosphorylation (Fig. 5) and AR localization (Fig. 6), mutations at
G421.46, G451.49 or N461.50 severely affect the folding and/or trafﬁcking
of AR. N461.50 is completely conserved in class A GPCRs [86], suggesting
that it is essential for receptor folding or function. The N46D ARmutant
was inactive, while the N46Q mutant showed the same response to
apelin as wild-type AR. This indicates that the amide moiety of the
sidechain is essential for proper AR folding and localization, but that
there is ability to accommodate variation in size. The reason that an N
to Q mutation at site 1.50 is not more prevalent in nature is thus an
interesting question.
In the currently solved crystal structures of GPCRs, the sidechain of
N1.50 is H-bonded to residue 7.46 in TM VII through the backbone
carbonyl oxygen of S7.46 (β1-adrenergic, β2-adrenergic, A2A adenosine,
dopamine D3, histamine H1, M2 muscarinic, S1P(1), κ-opioid and
μ-opioid receptors; [3–5,7,8,10–13]), C7.46 (CXCR4; [9]) or A7.46 (bovine
rhodopsin; [6]). This connection is retained in ourmodel andMD simu-
lations of AR (last 90 ns of each replicate), with an H-bond between the
N461.50 sidechain and the S3027.46 backbone carbonyl oxygen being
observed in 63.7% of simulation frames (e.g. Fig. 3E). An additional
52.1% of simulation frames have an H-bond between the sidechains of
N461.50 and D752.50 of TM II. The overwhelming majority (93.7%) of
simulation frames exhibit at least one of these H-bonding geometries,
and 22.0% of frames are consistent with H-bonding to both partners
simultaneously. A homologous contact between N461.50 and D732.50 is
observed in the histamine H1 receptor structure [7]. This leads to the
speculation that ﬂickering between these H-bond conﬁgurations
involving N1.50 may be a more widespread and functionally signiﬁcant
feature of GPCR dynamics.
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(Figs. 5 and 6) and are highly conserved in class A GPCRs (40–60% and
60–80% respectively, [86]) but do not show speciﬁc conserved inter-
helix interactions in the manner of N461.50. The importance of Gly
for inter-helical packing is well established [87] and these residues
may play a role for helix packing in AR. In addition, glycine allows
for helix ﬂexibility [88], which would be essential given the dynamic
nature of the nearby kink. Throughout our AR MD simulations, TM I is
bundled against both TM II and TM VII. Although the speciﬁc interac-
tions vary between frames, G421.46 lies against TM VII (predominantly)
or TM II (infrequently) while G451.49 interfaces exclusively with TMVII.
As a whole, the high sensitivity of residues near the TM I kink to muta-
tion highlights its importance for proper membrane localization of AR.
The amino acid identities at positions 1.47 and 1.48 are conserved
in 40–60% of class A GPCRs. Thr residues, as in AR, are quite rare, with
only 4% and 3% of class A GPCRs having Thr at positions 1.47 and 1.48,
respectively [86]. Even in the most homologous of the GPCRs, the AT1
receptor (~40–50% sequence identity in the TM domain [15]), the
corresponding positions are hydrophobic residues. However, neither
T431.47 nor T441.48 appears to be very sensitive to mutation in the
context of the activation studies employed herein.
In our ARmodel, these residues demonstrate considerable dynamics
and have the γ-OH groups protruding into the hydrophobic region
of the bilayer (see, e.g., headgroup phosphate positions illustrated
in Fig. 3D and F), with many frames of the simulation showing
H-bonding back to TM I of AR (Fig. 3E). During the replicateMD simula-
tions of AR in a hydrated bilayer, water molecules consistently became
associated with the γ-OH group of these sidechains within approxi-
mately 2 ns of simulation time. This does not preclude simultaneous
H-bonding to the main chain carbonyl O of other residues in TM I
(e.g. Fig. 3E). The variation in exact H-bonding to proximal water(s),
the main chain of TM I residues, or to both during the MD simulations
would lead to themodulation in kink properties and location described
above. Further illustrating that this plasticity is reasonable, mutation of
neither T431.47 nor T441.48 causes any appreciable loss of function.
4.2. The membrane-proximal E20/D23 anionic patch forms a likely binding
site for apelin
In the otherwise disordered N-terminal tail of AR55, we observed a
helix from D14 to K25 containing the residues E20 and D23 previously
shown to be essential for apelin binding to AR [26]. Residues E20 and
D23 are structured such that their anionic sidechains are in close prox-
imity (~9 Å apart) on the same face of the tail, both in our experimental
AR55 structure and in our MD simulations (Fig. 3C–D). The MD frame
used in Fig. 3D gives rise to the E20 and D23 sidechains facing outwards
upon superposition of theAR55NMRensemble, an orientation generally
upheld in tracking of the atomic species in closest proximity over the
entire pair of MD trajectories (Table 2). Speciﬁcally, >90% of frames
show DPPC molecules within the 10 most proximal moieties to the
anionic patch.
Although the N-terminal tail and TM I region of GPCRs are not
generally implicated in ligand binding, they are, e.g., important for
ligand speciﬁcity and efﬁcacy in the dopamine D1 and D5 receptors
[90]. A short helix preceding TM I has also been observed in at least
2 other GPCRs, in one case amphipathic [89] as with E20-K25 of AR,
and in the other not [10]. In the former case (the Y4 receptor), the
helical segment is postulated to undergo context speciﬁc restructuring
in the presence or absence of its peptidic ligand; in the latter case
(S1P1), this helix forms part of a movable cap for the binding pocket
for a lipid ligand. Given the diversity in class A GPCR N-terminal tail
length and structure, variant structuring and roles of N-terminal tails
seem reasonable. It should also be noted that inmost of theGPCR crystal
structures, this region is not resolved. Considering the N-terminal struc-
turing of the Y4 and S1P1 receptors in more detail, neither our MD sim-
ulation trajectories nor NMR structural data are indicative of capping ofthe TM domain, as in S1P1, by D14-E25 in AR (Fig. 3C–D). Instead, a
mechanism akin to that postulated for the Y4 receptor seems quite
reasonable.
Although the binding mechanism of apelin to AR is not yet known,
one popular model of peptide-GPCR interactions is a two-step mecha-
nism where the ligand initially binds the GPCR extracellular domain
and then works its way deeper into the GPCR TM domain to trigger
activation [91–94], with a ﬂy-casting mechanism frequently being
invoked as part of this process [94,95]. With the N-terminal tail of
AR55 being so ﬂexible and with multiple conformations observed in
the NMR data, it is possible that initial interactions of apelin with
AR55 (the ﬁrst step of the 2-step model) may be facilitated through
ﬂy-casting behavior. A general two-step mechanism ﬁts well with the
recent proposal of Iturrioz et al. that the C-terminus of apelin penetrates
deeply into the TM bundle during activation [27]. In this previous
study, mutagenesis results were rationalized in the context of a
bacteriorhodopsin-based homology model of AR to state that residues
W1544.50, F2576.44 and W2616.48 are in close proximity to the
C-terminal Phe of apelin in the bound state. Notably, some aspects of
the model presented herein are inconsistent with this previous model.
While our model shows a similar pocket of aromatic amino acids at
the putative apelin binding site, TM IV is not involved. W1544.50 is
distant from the binding pocket and, instead, forms a polar contact
with A692.44. This may help to rationalize the result of Iturrioz et al.
that mutation to W1544.50 severely affects folding and trafﬁcking of
AR without a requirement for proximity to the ligand-binding pocket.
The membrane-catalysis model, which we have proposed applies
to apelin-AR binding [24], adds a necessary precursor step to ligand-
receptor binding, where the ligand initially associates with the mem-
brane and, potentially, undergoes a structural change prior to receptor
recognition, binding and activation [96,97]. Apelin is highly cationic
(pI of apelin-17=12.5) and the anionic surface created by E20 and
D23 would therefore be a prime target for an electrostatic interaction.
In the absence of ligand, our MD simulations indicate that both E20
and D23 have prominent interactions with a small number of DPPC
molecules, but not with residues in other helices of AR (Table 2). The
zwitterionic lipid headgroups may stabilize the anionic patch until
they are displaced by the cationic ligand. This is reminiscent of the
ligand-induced conformational change postulated previously for the
Y4 receptor. Binding of apelin, very probably at the “RPRL” motif
[20,23], to E20 and/or D23 and subsequent liberation of the D14-E25
helix from the membrane would bring the relatively hydrophobic
C-terminus of apelin into sufﬁciently close proximity to ﬁnd its way
into its postulated binding site [27] within the AR helical bundle.
Upon binding, the dynamic nature of the N-terminal tail (Fig. 3F),
including the structurally converged anionic patch region, would per-
mit subsequent conformational excursion (or, ﬂy-casting) of the tail-
ligand complex allowing the unbound and relatively unencumbered
apelin C-terminus to access and bind in the core of the AR TM helical
bundle, inducing receptor activation.
4.3. Conclusions
This study illustrates a strong correlation between functionally
essential residues and structural features in the N-terminus and ﬁrst
TM segment of AR. In particular, we have identiﬁed an anionic
patch in the N-terminal tail of AR55 comprised of residues essential
for apelin binding. This patch is fully accessible on the protein surface
and poised in proximity to the membrane surface, providing an ideal
membrane-catalyzed binding site for a highly cationic membrane-
associated apelin ligand. A noncanonical kink in the otherwise helical
TM I segment is located near N461.50 and a pair of glycine residues
allowing close inter-helical packing. AR TM I is also unusually polar
in the vicinity of this kink, with two Thr sidechains oriented toward
the nonpolar tailgroup region of the bilayer. The divide and conquer
approach, expanded in scope using hybrid experimental data-
1482 D.N. Langelaan et al. / Biochimica et Biophysica Acta 1828 (2013) 1471–1483homology model derived MD simulations, has thus provided the ﬁrst
high-resolution structural detail about AR and strongly improved
insight into apelin binding to and activation of AR.
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